• Artiva Biotherapeutics updated wind-down estimates, projecting $10 million to $15 million in contract termination costs and AlloNK clinical trial closeout expenses.
• Workforce reduction costs are estimated at $17 million to $20 million, covering a planned cut of approximately 94% of employees.
• Most wind-down costs are expected in the fourth quarter of 2026, with workforce reductions completed in the first quarter of 2027.
• The wind-down follows the decision to discontinue AlloNK development while exploring strategic alternatives to maximize stockholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-453580), on November 09, 2026, and is solely responsible for the information contained therein.